| 0 (0%) | 09-27 14:45 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.66 |
1-year : | 12.45 |
| Resists | First : | 9.13 |
Second : | 10.66 |
| Pivot price | 8.31 |
|||
| Supports | First : | 8.06 |
Second : | 7.4 |
| MAs | MA(5) : | 8.42 |
MA(20) : | 8.27 |
| MA(100) : | 6.69 |
MA(250) : | 8.93  |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 63.2 |
D(3) : | 47.8 |
| RSI | RSI(14): 66.5 |
|||
| 52-week | High : | 19.93 | Low : | 5.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KURA ] has closed Bollinger Bands are 20.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.14 - 9.18 | 9.18 - 9.22 |
| Low: | 8.3 - 8.35 | 8.35 - 8.4 |
| Close: | 8.97 - 9.05 | 9.05 - 9.12 |
Sat, 27 Sep 2025
Kura Sushi USA (NASDAQ:KRUS) Upgraded to Hold at Wall Street Zen - MarketBeat
Thu, 25 Sep 2025
KURA: Promising Results from Ziftomenib AML Trial Published - GuruFocus
Thu, 25 Sep 2025
Kura Oncology’s ziftomenib meets primary endpoint in AML study - TipRanks
Thu, 25 Sep 2025
22% Complete Remission: Kura's Novel AML Drug Ziftomenib Shows Promise in Hard-to-Treat Blood Cancer - Stock Titan
Thu, 25 Sep 2025
World Sake Day: Sake Revolution LIVE! - City Guide New York
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 87 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 95.8 (%) |
| Shares Short | 8,410 (K) |
| Shares Short P.Month | 7,910 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.51 |
| Profit Margin | -236.8 % |
| Operating Margin | -475.4 % |
| Return on Assets (ttm) | -23 % |
| Return on Equity (ttm) | -51.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.33 |
| Sales Per Share | 0.95 |
| EBITDA (p.s.) | -2.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 125 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -4.03 |
| PEG Ratio | 0 |
| Price to Book value | 2.57 |
| Price to Sales | 9.43 |
| Price to Cash Flow | 6.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|